Table 2: Clinical and immunological characteristics of study participants.

Variables Case n (%) Control n (%) Total n (%) P-Value
CTX prophylaxis Yes 75 (62.5) 70 (58.33) 145(60.42) 0.253
No 45 (37.5) 50 (41.67) 95 (39.58)
INH prophylaxis Yes 51 (42.5) 46 (38.33) 97 (40.42) 0.255
No 69 (57.5) 74 (61.67) 143(59.58)
TB treatment history Yes 73(60.83) 75 (62.5) 148(61.67) 0.433
No 47 (39.17) 45 (37.5) 92(38.33)
Type of TB Pulmonary 34 (46.57) 29 (38.67) 63 (42.57) 0.426
Disseminated 21(28.76) 22 (29.33) 43 (29.06)
Unknown 18 (24.65) 24 (32) 42(28.37)
Clinical stage(WHO) Stage I 15 (12.5) 18 (15) 33(13.76) 0.018
Stage II 30(25) 35 (29.17) 65 (27.08)
Stage III 44 (36.67) 48 (40) 92 (38.33)
Stage IV 31 (25.83) 19 (15.83) 50 (20.83)
Eligibility reason CD4+ count 36 (30) 47 (39.17) 83 (34.58) 0.039
Clinical 27 (22.5) 18 (15) 45 (18.75)
CD4+ count & clinical 57 (47.5) 55 (45.83) 112 (46.67)
Baseline CD4+ count (cells/µL) Median 184.50 177 182.00 0.564
<200 59 (49.17) 58 (48.33) 117 (48.75)
200 −349 33 (27.5) 36 (30) 69 (28.75)
350 − 499 15 (12.5) 15 (12.5) 30 (12.5)
≥500 13(10.83) 11 (9.17) 24 (10)
Time elapsed till HAART initiation (in months) Within the same month 51(42.5) 39 (32.5) 90 (37.5) 0.038
1-24 45(37.5) 45 (37.5) 90 37.5
≥24 24 (20) 36 (30) 60(25)
Median duration on HAART (in months) 73 76.50 0.604
Median duration with HIV (in months) 80 94.50 0.140
Functional Status Working 90 (75) 93 (77.5) 183(76.25) 0.305
Ambulatory 30 (25) 27 (22.5 57 (23.75)
Regimen Change Yes 68 (56.67) 72 (60) 140(58.33) 0.32
No 52 (43.33) 48 (40) 100 (41.67)

CTX-Cotrimoxazole, INH- Isoniazid, TB- Tuberculosis, WHO- World Health Organization, CDC- Centers for Disease Control and Prevention; SD- Standard Deviation, CD4+- Cluster Differentiation, HAART- Highly Active Antiretroviral Therapy